LSE:AGY - Why did Allergy Therapeutics end its financial year with almost double the cash it held twelve months earlier, and what does the company expect next? Its trading update for the year ended 30 June 2026, published on 29 July 2026, points to a refinancing of its debt, steady Revenue growth and the launch of a new grass pollen product in Germany.
A Commercial Allergy Immunotherapy Business
Allergy Therapeutics plc, which trades on AIM under the code AGY, describes itself as a fully integrated commercial biotechnology company specialising in allergy immunotherapies. It sells treatments designed to modify the immune response to allergens such as pollen, and it develops next-generation products, including a peanut allergy candidate known as VLP Peanut. Germany and Spain are important markets for its existing products.
German regulation matters greatly to the group. Many allergen products there have been sold under a transitional arrangement, known as the TAV programme, which requires products to gain full approval to remain on the market. The company says this programme concludes in October 2026.
The 29 July Trading Update
In its 29 July 2026 announcement, the company said unaudited revenue for the year to 30 June 2026 was £59.9m, compared with £55.0m in the prior year, representing 9% growth on a reported basis. Second-half revenue was £23.6m against £21.0m a year earlier. At constant currency, it put full-year growth at around 5%, with Germany growing by more than 4% and Spain by 12%.
The company reported an unaudited cash balance of £24.2m at 30 June 2026, compared with £12.8m a year earlier. According to the update, it received £55m from the exercise of warrants, which it used to repay its Shareholder lenders, and it secured a new £40m Facility from Hayfin that was drawn in February 2026. The update also refers to a £50m unsecured facility from shareholder lenders that was undrawn at the year end.
Grassmuno and the Growth Outlook
The main commercial development was the launch in Germany of Grassmuno, which the company described as "the first subcutaneous grass pollen immunotherapy approved under the TAV programme." It said this launch "positions the Group for double digit revenue growth in the year to 30 June 2027."
Board changes followed. On 28 July 2026, the company appointed Helge Weiner-Trapness, previously Chief Strategy Officer, as Executive Chairman. Peter Jensen stepped down as Chairman after 13 years in the role, remaining on the board as a non-executive director, while Manuel Llobet continues as chief executive. The appointment announcement also referred to a potential dual primary listing on The Stock Exchange of Hong Kong.
Risks and Points to Watch
The figures in the trading update are unaudited, and the company said audited preliminary results would follow in October 2026. Those results should show the full profit and loss picture, which the update did not provide. The group has historically reported losses while funding research and development, so the balance between commercial revenue and development spending remains central.
Other uncertainties include the end of the German TAV programme, which could affect which products competitors keep on the market, the pace of Grassmuno uptake, currency movements given the euro-denominated sales base, and the cost of servicing the Hayfin facility. The potential Hong Kong listing is at an exploratory stage, and no terms or timetable were set out.
Conclusion
Allergy Therapeutics ended June 2026 with £24.2m of cash, up from £12.8m, because Warrant proceeds and a new £40m Hayfin facility reshaped its funding, according to its 29 July update. Revenue grew 9% to £59.9m, and management expects double-digit growth in the current year on the back of Grassmuno. October's audited results will show whether that stronger funding position is matched by improving profitability across the group's European commercial operations.






Please wait processing your request...